The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
A 43-year-old male with advanced hair loss is experimenting with alternative treatments, including red light therapy, microneedling, scalp massages, an oil mix, and ketoconazole shampoo, after previously experiencing side effects from finasteride and minoxidil. He noticed some minor changes with red light therapy but remains skeptical about significant improvement.
The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.
The conversation is about the effectiveness of Anagain, Capixyl, Procapil, and Redensyl for hair loss, and whether anyone has experience using these ingredients, sometimes in combination with Minoxidil.
The conversation is about using a Dr. Pen for microneedling on a widow's peak, with advice to use a depth of 1.25mm and hold it in place for 10 seconds. The user is also using minoxidil.
The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.
The user tried a product labeled as PP405 from Umbrella Labs for hair loss but saw no changes, and it was revealed to be a fake or misidentified product. The user is also using finasteride, minoxidil, and other treatments but is still experiencing hairline issues.
A potential treatment for alopecia involving a protein that calms hair follicles has shown promise in rats, but skepticism remains about its applicability to humans. Many users express doubt about the timeline for effective hair loss treatments, comparing it to past unfulfilled promises.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions observations about the Amla page on Examine.
Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.